Program
COM-701
Also written as “COM701”, “Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)” and “Cohort expansion: COM902 in combination with COM701 (both at the RDFE).”.
Its studies are mostly in Ovarian Neoplasms, led by Compugen.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Compugen | 31 open or running | phase 2since Mar 12, 2025 | Sep 10, 2018 | Mar 2027phase 2 · NCT06888921 |
Also a collaborator on its studies: Bristol-Myers Squibb.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 10, 2018First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT03667716 · 121 enrolled · United States
- Apr 15, 2020Phase 1 study in Ovarian NeoplasmsNCT04354246 · 94 enrolled · United States
- Mar 12, 2025Phase 2 study in Ovarian NeoplasmsNCT06888921 · 60 enrolled · United States, France, Israel
Ahead
- Mar 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT06888921
TargetBeta
“A humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06888921Ovarian Neoplasms · United States, France, Israel | 2 | Active, not recruiting | Mar 2027 | 60 |
| NCT04354246Ovarian Neoplasms · United States | 1 | Completed | Apr 1, 2026 | 94 |
| NCT03667716Ovarian Neoplasms · United States | 1 | Completed | Jan 30, 2024 | 121 |
How it is read
Names in the registry
- “COM701”, 2 entries
- “Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)”, 1 entry
- “Cohort expansion: COM902 in combination with COM701 (both at the RDFE).”, 1 entry
Codes read as this program: COM701.
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.